| APOLLOBIO |
APOLLOBIO |
92%
|
During the years ended December 31, 2025 and 2024, we derived 100% of our revenue from ApolloBio. |
| GOVERNMENT |
GOVERNMENT |
90%
|
A small number of licensing partners and government contracts have accounted for a substantial portion of our revenue. |
| LICENSING-PARTNERS |
LICENSING-PARTNERS |
90%
|
A small number of licensing partners and government contracts have accounted for a substantial portion of our revenue. |
| OPPENHEIMER-CO-INC |
OPPENHEIMER-CO-INC |
90%
|
the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, through the Sales Agent |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from INO graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from INO graph: f our proprietary device by the med… |
| SNYNF |
Sanofi |
72%
|
f our proprietary device by the medical community; • the prevalence and severity of any actual or perceived adverse side effects; • limitations or warnings contained in a product's FDA-approved label… |
| VXRT |
Vaxart, Inc. |
72%
|
Reciprocal relationship from VXRT graph: irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, produ… |
| AKESO-APOLLOBIO-CORPORATION |
AKESO-APOLLOBIO-CORPORATION |
62%
|
Item 1. Financial Statements 1 INOVIO PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2026 December 31, 2025 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 26,27… |
| APOLLOBIO-CORPORATION |
APOLLOBIO-CORPORATION |
62%
|
HSIL, but announced in 2023 that we were ceasing development for this indication in the United States. However, our collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of… |
| COLLABORATIVE-AGREEMENTS-APOLLOBIO-CORPORATION |
COLLABORATIVE-AGREEMENTS-APOLLOBIO-CORPORATION |
62%
|
rrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and developmen… |
| GENEONE-LIFE-SCIENCE-INC |
GENEONE-LIFE-SCIENCE-INC |
62%
|
rch 31, 2026 of 1.1 to 3.8 ye ars, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease pa… |
| INOVIO-ASIA-LLC |
INOVIO-ASIA-LLC |
62%
|
Item 1. Financial Statements 1 INOVIO PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2026 December 31, 2025 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 26,27… |
| OPERATIONS-INOVIO-PHARMACEUTICALS-INC |
OPERATIONS-INOVIO-PHARMACEUTICALS-INC |
62%
|
Item 1. Financial Statements 1 INOVIO PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2026 December 31, 2025 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 26,27… |
| PLUMBLINE-LIFE-SCIENCES-INC |
PLUMBLINE-LIFE-SCIENCES-INC |
62%
|
2023 that we were ceasing development for this indication in the United States. However, our collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in Chin… |
